# A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

> **NCT06756321** · EARLY_PHASE1 · RECRUITING · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 9 (estimated)

## Conditions studied

- Relapsed/refractory Lymphoma
- Relapsed/Refractory Leukemia

## Interventions

- **BIOLOGICAL:** anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06756321
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-18
- **Primary completion:** 2025-03-18
- **Final completion:** 2026-03-18
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756321, "A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06756321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*